AI assistant
Jade Biosciences, Inc. — Director's Dealing 2021
Jun 30, 2021
33383_dirs_2021-06-29_583a1f3d-6d87-4c5c-8099-3fccc9dd060a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Aerovate Therapeutics, Inc. (AVTE)
CIK: 0001798749
Period of Report: 2021-06-29
Reporting Person: Gillies Hunter (Chief Medical Officer)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $1.74 | 2030-09-03 | Common Stock (16097) | Direct | |
| Stock Option (Right to Buy) | $1.74 | 2030-09-03 | Common Stock (24108) | Direct | |
| Stock Option (Right to Buy) | $2.144 | 2031-04-01 | Common Stock (16294) | Direct | |
| Stock Option (Right to Buy) | $2.144 | 2031-04-01 | Common Stock (109640) | Direct |
Footnotes
F1: 10% of this option became vested and exercisable on May 1, 2020, with an additional 22.5% vested on May 1, 2021 and the remainder vesting in 36 substantially equal monthly installments thereafter.
F2: 25% of this option shall vest and become exercisable on August 1, 2021, with the remainder vesting in 36 substantially equal monthly installments thereafter.
F3: This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vested on May 2, 2021.
F4: This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on July 4, 2021.